Tag Archives: NASDAQ:EPZM

Cowen & Co. Maintains a Buy Rating on Epizyme (EPZM)

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Epizyme (EPZM – Research Report), with a price target of $18. The company’s shares closed yesterday at $11.46. According to TipRanks.com, Werber is a

Oppenheimer Initiates a Buy Rating on Epizyme (EPZM)

Oppenheimer analyst Leland Gershell initiated coverage with a Buy rating on Epizyme (EPZM – Research Report) today and set a price target of $18. The company’s shares closed yesterday at $13.76. Gershell commented: “We are assuming coverage of EPZM with

Cowen & Co. Keeps a Buy Rating on Epizyme (EPZM)

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Epizyme (EPZM – Research Report), with a price target of $18. The company’s shares opened today at $12.76. According to TipRanks.com, Werber is ranked

Epizyme (EPZM) Receives a Buy from Oppenheimer

Oppenheimer analyst Leland Gershell reiterated a Buy rating on Epizyme (EPZM – Research Report) today and set a price target of $27. The company’s shares opened today at $7.94. Gershell observed: “Beyond providing increased visibility on tazemetostat’s path to approval

Cowen & Co. Thinks Epizyme’s Stock is Going to Recover

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $8.30, close to its 52-week low of $7.61. According to TipRanks.com, Nadeau is a 5-star analyst with an average

Oppenheimer Thinks Epizyme’s Stock is Going to Recover

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $27. The company’s shares opened today at $8.30, close to its 52-week low of $7.74. Cann wrote: